9TH ANNUAL RIDE TO CONQUER CANCER - JULY 8-9, 2017

Dollars at work

IMPACT & USE OF FUNDS
Jewish General Hospital

Since 2009, the Enbridge Ride to Conquer Cancer has raised $47 million and is currently Quebec’s largest cycling fundraiser. The Ride to Conquer Cancer series is Canada’s largest peer-to-peer fundraising event.

Funds raised through The Enbridge Ride to Conquer Cancer support vital cancer research, treatment, care and prevention programs at the Jewish General Hospital’s Segal Cancer Centre and other partners across Quebec.

The Jewish General Hospital’s Segal Cancer Centre is a leader in Quebec in implementing a focused and comprehensive approach to fighting cancer through a combination of medical treatment, patient care, family support and scientific research. The centre is one of few in the world which offers a combination of strong research and highly skilled clinicians under one roof.

Their world-leading doctors, researchers and scientists at the Jewish General Hospital are working to develop new technologies in the areas of molecular diagnostics, functional imaging, biomarkers, molecular target discovery and validation, and advanced targeted radiation therapy.

Funds raised through The Ride are put to use immediately to attract and retain world-leading doctors, scientists and researchers to implement the most promising cancer research programs and treatments. The programs at the Segal Cancer Centre include:

  • First High Intensity Focused Ultrasound (HIFU) machine in North America:
    This advanced type of targeted therapy can effectively destroy specific areas of cancer within the prostate, while preserving normal prostate tissue and function, enabling the Division of Urology to become the first in Canada to treat prostate cancer with focal therapy and to be a centre expertise for this technology in the country.
  • Intraoperative Radiation Therapy (IORT):
    First centre in Canada to offer Intraoperative Radiation Therapy (IORT) for the treatment of early stage breast cancers, which replaces 20-30 radiotherapy sessions with one single radiotherapy session.
  • Creation of first Molecular Pathology Centre in Quebec:
    This centre enables to determine the complete DNA profile for a single patient, and to identify the genetic mutations for this patient. This centre includes sophisticated equipment (Triple Quadrupole Liquid Chromatography/Mass Spectrometry system, Focused Ultrasonicator, Nitrogen Gas Generator, inverted tissue culture microscope and slide scanner) which needed to be purchased to allow further study of new biomarkers.
  • First and only clinical centre for the pan-Canadian program of proteomics:
    Creation of the first and only clinical centre for the pan-Canadian program of proteomics, the study of proteins expressed into the blood by cancer cells. Proteomics allows to identify the most effective treatment for a patient based on their unique case.
  • Nanorobotics (world innovation):
    Research project with Polytechnique for the use of a bacteria that consumes iron for the controlled distribution of chemotherapy using the magnetic fields of MRI.

Funds raised through The Ride also power cancer initiatives at the Ride’s partner institutions across Quebec:

  • The Centre of Clinical Research and Evaluative Oncology (CCREO) - With a staff of more than 50 oncologists, researchers and associates, who work closely with a team of researchers from the UHCG Cancer Research Department to develop and enhance research programs in the fields of oncology, X-ray and genomics at the CHU de Quebec.
  • The acquisition of high-tech machines and equipment and the enhancements of treatments via the “Fondation régionale pour la santé de Trois-Rivières (RSTR)”. The optimization of care allows patients to benefit from more accurate diagnosis and to receive more specialized treatments within the community, eliminating the need to commute to larger centres and benefit from the support of their friends and family.